Market closed· · CHF · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
New funds will enable patient follow-up and data collection in the AAA-SHAPE trial and further progress in the FLAGSHIP study.
SAN JOSE, Calif., August 24, 2026--Shape Memory Medical Inc., developer of proprietary shape memory polymer technology for endovascular embolization, today announced the closing of a $10 million convertible note financing led by new investor August Global Partners (AGP), joined by fellow new investor Taiwania Capital.
Crystalys Therapeutics Inc. ('Crystalys' or 'the Company'), a clinical-stage biopharmaceutical company addressing the significant unmet medical needs of people living with gout, today announced the closing of an oversubscribed $130 million Series B financing to support the late-stage global clinical development and commercialization preparation of dotinurad, a next-generation, once daily, oral URAT1 inhibitor with the potential to deliver best-in-class safety and efficacy for the treatment of go
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.